Sherif Raafat Zikry Abdel-Misih

Dr. Sherif Raafat Zikry Abdel-Misih

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2016 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SBShayna Brathwaite
Shayna Brathwaite
JRJonathan Rock
Jonathan Rock
MYMartha M. Yearsley
Martha M. Yearsley
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
LWLai Wei
Lai Wei
SASherif Raafat Zikry Abdel-Misih
Sherif Raafat Zikry Abdel-Misih

13 June 2016 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SBShayna Brathwaite
Shayna Brathwaite
MYMartha M. Yearsley
Martha M. Yearsley
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
LWLai Wei
Lai Wei
CSCarl R. Schmidt
Carl R. Schmidt
SASherif Raafat Zikry Abdel-Misih
Sherif Raafat Zikry Abdel-Misih
Introduction Mixed adeno-neuroendocrine carcinoma (MANEC) is a rare pathologic diagnosis recently defined by the World Health Organization (WHO) in 2010. Prior to definition by the WHO, tumors with both adenocarcinoma and neuroendocrine components were given multiple pathologic designations making it difficult to characterize the disease. The aim of our study is to better characterize MANEC to better understand it’s natural history to influence patient care and positively impact outcomes. Materials and Methods The Surveillance, Epidemiology and End Results (SEER) program database was queried for all patients age 18 years of age or older between 1973-2012 who had the diagnosis composite carcinoid (n=249) of the appendix. Composite carcinoid tumors refer to tumors that have both adenocarcinoma and carcinoid tumor components present, consistent with that pathologic diagnosis MANEC. For comparison, the database was also queried for carcinoid tumor of the appendix (n=950), signet ring cell carcinoma of the appendix (n=579) and goblet cell carcinoid (GCC) tumors of the appendix (n=944). The data was retrospectively reviewed and clinicopathologic characteristics, treatment regimens and survival data were obtained. Results The median age of diagnosis of MANEC tumors was 58 years of age. Eighty percent of patients were white and 49% were female. Fifty-four percent of patients underwent hemicolectomy and 31% had partial/subtotal colectomy as their surgical management. Median overall survival for MANEC was 6.5 years (95% CI 4.5-9.7), which was statistically significantly shorter (p<0.0001) in comparison to 13.8 years (95% CI 12.1-16.5) for GCC, 2.1 years (95% CI 1.8-2.3) for signet ring cell carcinoma and 39.4 years (95% CI 37.1 – NA) for carcinoid tumors. Discussion MANEC is a more aggressive clinical entity than both GCC of the appendix and carcinoid tumors of the appendix. Based on these findings, patients with MANEC tumors should undergo aggressive multidisciplinary cancer management.

10 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBEliza W Beal
Eliza W Beal
LSLorena P. Suarez-Kelly
Lorena P. Suarez-Kelly
CKCharles W. Kimbrough
Charles W. Kimbrough
Fabian M. JohnstonFabian M. Johnston
Fabian M. Johnston
JGJonathan Greer
Jonathan Greer
JCJordan Cloyd
Jordan Cloyd
Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.

12 December 2016 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
SASherif Raafat Zikry Abdel-Misih
Sherif Raafat Zikry Abdel-Misih
LWLai Wei
Lai Wei
ABAl B. Benson
Al B. Benson
SCSteven Cohen
Steven Cohen
LLLily Lai
Lily Lai
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
Background: Nodal status has long been considered pivotal to oncologic care, staging, and management. This has resulted in the establishment of rudimentary metrics regarding adequate lymph node yield in colon and rectal cancers for accurate cancer staging. In the era of neoadjuvant treatment, the implications of lymph node yield and status on patient outcomes remains unclear. Patient and Methods: This study included 1,680 patients with locally advanced rectal cancer from the NCCN prospective oncology database stratified into 3 groups based on preoperative therapy received: no neoadjuvant therapy, neoadjuvant chemoradiation, and neoadjuvant chemotherapy. Clinicopathologic characteristics and survival were compared between the groups, with univariate and multivariate analyses undertaken. Results: The clinicopathologic characteristics demonstrated statistically significant differences and heterogeneity among the 3 groups. The neoadjuvant chemoradiation group demonstrated the statistically lowest median lymph node yield (n=15) compared with 17 and 18 for no-neoadjuvant and neoadjuvant chemotherapy, respectively (P<.0001). Neoadjuvant treatment did impact survival, with chemoradiation demonstrating increased median overall survival of 42.7 compared with 37.3 and 26.6 months for neoadjuvant chemotherapy and no-neoadjuvant therapy, respectively (P<.0001). Patients with a yield of fewer than 12 lymph nodes had improved median overall survival of 43.3 months compared with 36.6 months in patients with 12 or more lymph nodes (P=.009). Multivariate analysis demonstrated that neither node yield nor status were predictors for overall survival. Discussion: This analysis reiterates that nodal yield in rectal cancer is multifactorial, with neoadjuvant therapy being a significant factor. Node yield and status were not significant predictors of overall survival. A nodal metric may not be clinically relevant in the era of neoadjuvant therapy, and guidelines for perioperative therapy may need reconsideration. Background: Nodal status has long been considered pivotal to oncologic care, staging, and management. This has resulted in the establishment of rudimentary metrics regarding adequate lymph node yield in colon and rectal cancers for accurate cancer staging. In the era of neoadjuvant treatment, the implications of lymph node yield and status on patient outcomes remains unclear. Patient and Methods: This study included 1,680 patients with locally advanced rectal cancer from the NCCN prospective oncology database stratified into 3 groups based on preoperative therapy received: no neoadjuvant therapy, neoadjuvant chemoradiation, and neoadjuvant chemotherapy. Clinicopathologic characteristics and survival were compared between the groups, with univariate and multivariate analyses undertaken. Results: The clinicopathologic characteristics demonstrated statistically significant differences and heterogeneity among the 3 groups. The neoadjuvant chemoradiation group demonstrated the statistically lowest median lymph node yield (n=15) compared with 17 and 18 for no-neoadjuvant and neoadjuvant chemotherapy, respectively (P<.0001). Neoadjuvant treatment did impact survival, with chemoradiation demonstrating increased median overall survival of 42.7 compared with 37.3 and 26.6 months for neoadjuvant chemotherapy and no-neoadjuvant therapy, respectively (P<.0001). Patients with a yield of fewer than 12 lymph nodes had improved median overall survival of 43.3 months compared with 36.6 months in patients with 12 or more lymph nodes (P=.009). Multivariate analysis demonstrated that neither node yield nor status were predictors for overall survival. Discussion: This analysis reiterates that nodal yield in rectal cancer is multifactorial, with neoadjuvant therapy being a significant factor. Node yield and status were not significant predictors of overall survival. A nodal metric may not be clinically relevant in the era of neoadjuvant therapy, and guidelines for perioperative therapy may need reconsideration.

1 June 2021 in Surgical Oncology
Verified
Journal Article
Closed access
JWJason T. Wiseman
Jason T. Wiseman
SASherif Raafat Zikry Abdel-Misih
Sherif Raafat Zikry Abdel-Misih
EBEliza W. Beal
Eliza W. Beal
MZMohammad Y. Zaidi
Mohammad Y. Zaidi
CSCharles A. Staley
Charles A. Staley
JCJordan Cloyd
Jordan Cloyd

7 May 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JCJc Chen
Jc Chen
EBEliza W Beal
Eliza W Beal
JHJohn Hays
John Hays
Tim PawlikTim Pawlik
Tim Pawlik
SASherif Raafat Zikry Abdel-Misih
Sherif Raafat Zikry Abdel-Misih
JCJordan Cloyd
Jordan Cloyd